---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-194511"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:32:59.886673+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study

## Summary
- 200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels
- Individual during acute phase response showed 20.6 µM total AAT and 10.3 µM M-AAT, first demonstration of restored physiological production
- Single 400 mg dose achieved 12.8 µM total AAT and 5.3 µM M-AAT; monthly dosing supported
- GSK holds exclusive global license for WVE-006; Wave eligible for up to $525M milestones plus royalties
- Data support monthly or less frequent subcutaneous dosing; 400 mg multidose cohort data expected Q1 2026

## SEC filing metadata
- accession: 0001193125-25-194511
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525194511/0001193125-25-194511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525194511/d67509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-194511
- JSON: https://secwatch.observer/filing/0001193125-25-194511.json
- Plain text: https://secwatch.observer/filing/0001193125-25-194511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.